Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
USA Life Sciences Database,
Xiidra (lifitegrast ophthalmic solution) 5% fits strategically within industry-leading USD 4.6 billion Novartis ophthalmic…